Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1/2 1

Status

Completed 4

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 6Other hematologic neoplasm 5Gynecologic 5Plasma cell 4Gastrointestinal 4Breast 4Myeloid 3Genitourinary 3Dermatologic 3CNS 3Tumor-Agnostic 1

Conditions

Vomiting 2Nausea 2Colonic Neoplasms 2Rectal Neoplasms 1Pancreatic Neoplasms 1Lymphoma 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Bile Duct Neoplasms 1

Interventions

Fluorouracil 286Oxaliplatin 274Gemcitabine 222Capecitabine 221Leucovorin 219Bevacizumab 200Irinotecan 170pembrolizumab 141Cisplatin 132Cetuximab 111Radiotherapy 109Sorafenib 75Nivolumab 75130-nm albumin-bound paclitaxel 64Paclitaxel 63Albumin-Bound Paclitaxel 63Docetaxel 61Erlotinib Hydrochloride 57Panitumumab 56Radiosurgery 47Folfox protocol 46regorafenib 45Sunitinib 40Radiation 39Magnetic Resonance Spectroscopy 38durvalumab 33Surgical Procedures, Operative 33Ramucirumab 33Trastuzumab 32Cyclophosphamide 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Aprepitant × Gastrointestinal × Clear all
NCT01851369 2024-05-08

TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
93 enrolled 27 charts
GastrointestinalLymphoid

Colonic Neoplasms, Lymphoma

NCT01504711 2021-04-08

Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy

Barbara Ann Karmanos Cancer Institute

Phase NA Completed
30 enrolled 12 charts
Gastrointestinal

Gastrointestinal Neoplasms

NCT01534637 2018-08-15

Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer

Wake Forest University Health Sciences

Phase 2 Completed
22 enrolled 9 charts
Gastrointestinal

Bile Duct Neoplasms, Nausea, Pancreatic Neoplasms, Vomiting

NCT00381862 2017-06-12

Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

OHSU Knight Cancer Institute

Phase 2 Completed
54 enrolled 7 charts
Gastrointestinal

Colonic Neoplasms, Nausea, Rectal Neoplasms, Vomiting, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡